Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nitric oxide + epoprostenol
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Nitric oxide + epoprostenol is a combination therapy consisting of inhaled nitric oxide (iNO) and inhaled epoprostenol (also known as prostacyclin or iPGI2). This combination has been investigated by Stanford University for the management of right ventricular failure and pulmonary hypertension in patients undergoing cardiac surgery, specifically heart transplantation or left ventricular assist device (LVAD) placement. Nitric oxide acts as a potent pulmonary vasodilator by stimulating soluble guanylate cyclase, which increases cyclic guanosine monophosphate (cGMP) levels in vascular smooth muscle. Epoprostenol acts through the prostacyclin receptor (IP receptor) to induce vasodilation and inhibit platelet aggregation via increased cyclic adenosine monophosphate (cAMP). The combined administration aims to achieve a synergistic reduction in pulmonary vascular resistance, thereby improving right heart function and hemodynamic stability in the post-operative period.
- Other names
- inhaled nitric oxide + inhaled prostacycliniNO + iPGI2
02
Targets
PTGIR (Prostanoid IP Receptor)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on nitric oxide + epoprostenol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nitric oxide + epoprostenol.